

MicroRNA Expression in Dendritic Cells for Immune Regulation

► Asset Overview

Product Type	Gene therapy
Indication	Immunology, Oncology
Current Stage	Discovery
Target(MoA)	Immune regulation
Brief Description	<ul style="list-style-type: none">• Found over- or under-expression of certain microRNA in dendritic cells affects their ability to direct immune response• Once modified, these dendritic cells could be used in cellular therapy to treat a wide range of immune conditions and diseases• For example, this cellular therapy technology has the potential to replace long-term pharmaceutical immunosuppression therapy, be utilized as a more benign cancer immunotherapy, and has potential as a immunotherapeutic adjuvant
Organization	Stanford University

► Differentiation

□ Advantages

- Long-term to permanent effects: Eliminate the need for lifelong medications for immunosuppression
- More benign and targeted therapy than current cancer treatments

494 **MicroRNA Expression in Dendritic Cells for Immune Regulation**

► Intellectual Property

Patent No.	US 9623040 B2
Application Date	2015.07.10
Status	Registered
Country	US

► Contact Information

Contact Person	Denise Lew
Email	denise.lew@stanford.edu
URL	http://techfinder.stanford.edu/technologies/S14-177_microma-over-and-under-expression